Colleen Kelley
Emory University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Colleen Kelley as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:02 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07215325 · Got Doxy- 'Flipping the Script' on STI PEPEmory University · recruiting · Sexually Transmitted Infections (STI) · principal investigator
- Ph4NCT06545656 · Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis RegimensEmory University · completed · Sexually Transmitted Infection · principal investigator
- Ph4NCT05853120 · Doxy-Post-exposure ProphylaxisEmory University · completed · Sexually Transmitted Diseases · principal investigator
- Ph1NCT05184452 · A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult ParticipantsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · HIV Infections · study chair
- Ph4NCT04860505 · Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis RegimensEmory University · completed · Sexually Transmitted Diseases · principal investigator
- N/ANCT04531943 · Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender WomenEmory University · completed · HIV Prevention · principal investigator
- Ph4NCT04298697 · Biomarkers for Event-driven PrEP AdherenceEmory University · completed · Human Immunodeficiency Virus · principal investigator
- Ph4NCT04039217 · Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSMEmory University · completed · ART, HIV · principal investigator
- Ph1NCT03976752 · Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis RegimensEmory University · completed · HIV/AIDS · principal investigator
- Ph1NCT03856996 · A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected CellsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · HIV Infections · study chair
- Ph1NCT03472963 · Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.Emory University · completed · HIV Infections · principal investigator
- Ph1NCT02985996 · Body Compartment PK for New HIV Pre-exposure Prophylaxis ModalitiesEmory University · completed · HIV Infections · principal investigator
- Ph4NCT02401230 · PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIVEmory University · completed · HIV · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Center for AIDS Research at Emory UniversityP30AI050409 · NIAID · EMORY UNIVERSITY · fiscal years 2022 to 2026 · $2,249,949 awarded in 2026Same name and institution; not confirmed by an ID
- Defining Sex-Specific Systemic and Gut Inflammatory Profiles in People Living with HIVR01AI174933 · NIAID · EMORY UNIVERSITY · fiscal years 2023 to 2026 · $781,138 awarded in 2026Same name and institution; not confirmed by an ID
- Emory Training Program in Translational Research to End the HIV EpidemicT32AI157855 · NIAID · EMORY UNIVERSITY · fiscal years 2021 to 2026 · $389,597 awarded in 2026Same name and institution; not confirmed by an ID
- Emory-CDC CTUUM1AI069418 · NIAID · EMORY UNIVERSITY · fiscal years 2023 to 2026 · $465,482 awarded in 2026Same name and institution; not confirmed by an ID
- The Effects of Doxycycline on Inflammation and the Microbiome: 'Flipping the Script' on STI PEPR01AI192319 · NIAID · EMORY UNIVERSITY · fiscal years 2025 to 2026 · $784,536 awarded in 2026Grant number is on one of their registry trials
- Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs among Young Black MSMR01MH122341 · NIMH · EMORY UNIVERSITY · fiscal years 2020 to 2024 · $723,606 awarded in 2024Same name and institution; not confirmed by an ID
- Understanding the rectal mucosal effects of cross-sex hormone therapy among US and Thai transgender womenR01AI147839 · NIAID · EMORY UNIVERSITY · fiscal years 2019 to 2023 · $669,117 awarded in 2023Grant number is on one of their registry trials
- Gender as a biological variable: transcriptomic analysis of rectal mucosal immune cells among transgender peopleR21AI157911 · NIAID · EMORY UNIVERSITY · fiscal years 2021 to 2022 · $195,625 awarded in 2022Grant number is on one of their registry trials
- STI and Implications for HIV Transmission and PreventionR01HD092033 · NICHD · EMORY UNIVERSITY · fiscal years 2017 to 2020 · $415,894 awarded in 2020Same name and institution; not confirmed by an ID
- Understanding Rectal HIV transmission among At-risk MSM: Age, Intercourse, and Mucosal InjurR01AI128799 · NIAID · EMORY UNIVERSITY · fiscal years 2017 to 2020 · $552,745 awarded in 2020Same name and institution; not confirmed by an ID
- Defining the rectal mucosa in MSM at risk of HIV infectionK23AI108335 · NIAID · EMORY UNIVERSITY · fiscal years 2013 to 2017 · $135,159 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:02 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.N Engl J Med · 2021777 citationsRCR 56.1
- 244 citationsRCR 83.6
- Short- and long-term outcomes of children with complex regional pain syndrome type I treated with exercise therapy.Clin J Pain · 1999193 citationsRCR 7.5
- 164 citationsRCR 4.2
- Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.Clin Pharmacol Ther · 2003144 citationsRCR 5.2
- Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.Lancet Respir Med · 202298 citationsRCR 6.1
- Trial of a disease management program to reduce hospital readmissions of the chronically critically ill.Chest · 200588 citationsRCR 2.4
- Impact of a disease management program upon caregivers of chronically critically ill patients.Chest · 200569 citationsRCR 2.1
- Home-based psychoeducational and mailed information programs for stroke-caregiving dyads post-discharge: a randomized trial.Disabil Rehabil · 201469 citationsRCR 3.8
- Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.Lancet Respir Med · 202259 citationsRCR 3.7